Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 6/20 | 0.60 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.60 |
| ▸ | TNF | P01375 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.59 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.59 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CSF1R | P07333 | 1/20 | 0.55 |
| ▸ | QPCT | Q16769 | 2/20 | 0.55 |
| ▸ | BRD4 | O60885 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6047768 | 0.89 | CYP11B1 (0.60) | CYP11B1CYP11B2TNFHTTALDH1A1 | |
| SCHEMBL27441640 | 0.85 | QPCT (0.55) | CYP11B1CYP11B2HTTALDH1A1HPGD | |
| SCHEMBL1621828 | 0.84 | ALDH1A1 (0.54) | CYP11B1CYP11B2TNFHTTALDH1A1 | |
| SCHEMBL29424815 | 0.83 | QPCT (0.53) | CYP11B1CYP11B2HTTALDH1A1HPGD | |
| SCHEMBL22533864 | 0.83 | QPCT (0.53) | CYP11B1CYP11B2HTTALDH1A1HPGD | |
| SCHEMBL12771538 | 0.82 | HTT (0.72) | CYP11B1CYP11B2TNFHTTALDH1A1 | |
| SCHEMBL30138392 | 0.82 | HTT (0.72) | CYP11B1CYP11B2TNFHTTALDH1A1 | |
| SCHEMBL15345063 | 0.81 | CYP11B1 (0.68) | CYP11B1CYP11B2TNFHTTALDH1A1 | |
| SCHEMBL3102063 | 0.81 | QPCT (0.65) | CYP11B1CYP11B2HTTALDH1A1L3MBTL1 | |
| SCHEMBL15825080 | 0.81 | QPCT (0.58) | CYP11B1CYP11B2HTTALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| EP-1646614-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2008-09-10 | — | — | EP | disclosed |
| EP-1432417-B1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | EP | disclosed |
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | disclosed |
| US-7041668-B2 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| EP-1646614-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
| WO-2005002520-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | CDKL3, CCNL2, CDKL1 | CYP11B1 1530/4885CYP11B2 1570/4885TNF 4844/4885 |
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | CYP11B1 640/4885CYP11B2 607/4885TNF 4147/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | CYP11B1 640/4885CYP11B2 607/4885TNF 4147/4885 |
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNN1 | CYP11B1 499/4885CYP11B2 527/4885TNF 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.